The University of Southampton
University of Southampton Institutional Repository

Dynamics of BCR-ABL mRNA expression in first-line therapy of chronic myelogenous leukemia patients with imatinib or interferon alpha/ara-C

Dynamics of BCR-ABL mRNA expression in first-line therapy of chronic myelogenous leukemia patients with imatinib or interferon alpha/ara-C
Dynamics of BCR-ABL mRNA expression in first-line therapy of chronic myelogenous leukemia patients with imatinib or interferon alpha/ara-C
We sought to determine dynamics of BCR-ABL mRNA expression levels in 139 patients with chronic myelogenous leukemia (CML) in early chronic phase, randomized to receive imatinib (n=69) or interferon (IFN)/Ara-C (n=70). The response was sequentially monitored by cytogenetics from bone marrow metaphases (n=803) and qualitative and quantitative RT-PCR from peripheral blood samples (n=1117). Complete cytogenetic response (CCR) was achieved in 60 (imatinib, 87%) vs 10 patients (IFN/Ara-C, 14%) after a median observation time of 24 months. Within the first year after CCR, best median ratio BCR-ABL/ABL was 0.087%, (imatinib, n=48) vs 0.27% (IFN/Ara-C, n=9, P=0.025). BCR-ABL was undetectable in 25 cases by real-time PCR, but in only four patients by nested PCR. Median best response in patients with relapse after CCR was 0.24% (n=3) as compared to 0.029% in patients with continuous remission (n=52, P=0.029). We conclude that (i) treatment with imatinib in newly diagnosed CML patients is associated with a rapid decrease of BCR-ABL transcript levels; (ii) nested PCR may reveal residual BCR-ABL transcripts in samples that are negative by real-time PCR; (iii) BCR-ABL transcript levels parallel cytogenetic response, and (iv) imatinib is superior to IFN/Ara-C in terms of the speed and degree of molecular responses, but residual disease is rarely eliminated.
epidemiology, male, fusion proteins, chronic, cytogenetics, antineoplastic agents, interferon-alpha, multicenter studies, cytarabine, germany, diagnosis, messenger, disease, middle aged, antineoplastic, recurrence, research support, patients, piperazines, treatment outcome, female, blood, prospective studies, metaphase, myeloid, genetics, proteins, prognosis, bone, bcr-abl, cross-over studies, protein, pyrimidines, non-U.S.gov't, humans, antimetabolites, leukemia, rna, bone marrow, aged, time, metabolism, observation, administration & dosage, adult, comparative study, therapy, risk factors, drug therapy
0887-6924
2392-2400
Muller, M.C.
f443fd83-3203-42b1-a110-3532d65f2a2e
Gattermann, N.
d23fdb88-810e-4a56-af55-ddcbb2e57961
Lahaye, T.
97333448-5919-4fa2-b1d7-d4bcc51733f3
Deininger, M.W.
1432757e-04e8-4426-8ead-83bfd1a655f5
Berndt, A.
7b346490-236d-458a-8224-e5d8ca0ca0d4
Fruehauf, S.
4dbbc11f-8ab7-4cc4-b508-35a2d190bb84
Neubauer, A.
8463ae1b-e70e-4176-9bc2-b83184e40561
Fischer, T.
aba70ee0-35f0-416e-a436-658edcd9b1eb
Hossfeld, D.K.
ef5b628a-3e37-4705-a211-7a314de57042
Schneller, F.
4c3a5379-5858-4abd-8f17-75b9f5d48a7e
Krause, S.W.
b6ec5c16-fd7a-409c-9dc3-613c89771f90
Nerl, C.
a3e4aed3-20e0-4928-9ff2-0e77175a9742
Sayer, H.G.
d7fdb285-ed5f-455f-9265-0a7a36158196
Ottmann, O.G.
b5909f66-cc4e-462e-8aef-66ded21ecf07
Waller, C.
f8fe1021-bff0-4a61-b7a3-abd6283b51f3
Aulitzky, W.
0682ba7b-4e4b-43fe-bd8d-78b69313f4a6
Le Coutre, P.
5ed4a3ef-f787-4950-b8ae-38103811fea6
Freund, M.
689ed2f3-5458-4858-a1ab-4a5ca4c99749
Merx, K.
119693a0-18cb-4474-83d1-776c685ccac8
Paschka, P.
3a97b303-face-4de6-8a34-e3c6bd98c0f9
Konig, H.
9bfea440-ff35-43c8-b326-39e0917ab71a
Kreil, S.
2404ac13-cdaa-43a3-913b-adceb79e598f
Berger, U.
440811e1-e1c2-4f54-a435-b6dd61853857
Gschaidmeier, H.
46d97d80-f9c6-4286-af8a-407d4a282058
Hehlmann, R.
753d719b-7bf8-4f74-bfdc-6d5d47e5d2c7
Hochhaus, A.
4c0b9da4-adfa-4253-8af7-78cec9e9a24f
Muller, M.C.
f443fd83-3203-42b1-a110-3532d65f2a2e
Gattermann, N.
d23fdb88-810e-4a56-af55-ddcbb2e57961
Lahaye, T.
97333448-5919-4fa2-b1d7-d4bcc51733f3
Deininger, M.W.
1432757e-04e8-4426-8ead-83bfd1a655f5
Berndt, A.
7b346490-236d-458a-8224-e5d8ca0ca0d4
Fruehauf, S.
4dbbc11f-8ab7-4cc4-b508-35a2d190bb84
Neubauer, A.
8463ae1b-e70e-4176-9bc2-b83184e40561
Fischer, T.
aba70ee0-35f0-416e-a436-658edcd9b1eb
Hossfeld, D.K.
ef5b628a-3e37-4705-a211-7a314de57042
Schneller, F.
4c3a5379-5858-4abd-8f17-75b9f5d48a7e
Krause, S.W.
b6ec5c16-fd7a-409c-9dc3-613c89771f90
Nerl, C.
a3e4aed3-20e0-4928-9ff2-0e77175a9742
Sayer, H.G.
d7fdb285-ed5f-455f-9265-0a7a36158196
Ottmann, O.G.
b5909f66-cc4e-462e-8aef-66ded21ecf07
Waller, C.
f8fe1021-bff0-4a61-b7a3-abd6283b51f3
Aulitzky, W.
0682ba7b-4e4b-43fe-bd8d-78b69313f4a6
Le Coutre, P.
5ed4a3ef-f787-4950-b8ae-38103811fea6
Freund, M.
689ed2f3-5458-4858-a1ab-4a5ca4c99749
Merx, K.
119693a0-18cb-4474-83d1-776c685ccac8
Paschka, P.
3a97b303-face-4de6-8a34-e3c6bd98c0f9
Konig, H.
9bfea440-ff35-43c8-b326-39e0917ab71a
Kreil, S.
2404ac13-cdaa-43a3-913b-adceb79e598f
Berger, U.
440811e1-e1c2-4f54-a435-b6dd61853857
Gschaidmeier, H.
46d97d80-f9c6-4286-af8a-407d4a282058
Hehlmann, R.
753d719b-7bf8-4f74-bfdc-6d5d47e5d2c7
Hochhaus, A.
4c0b9da4-adfa-4253-8af7-78cec9e9a24f

Muller, M.C., Gattermann, N., Lahaye, T., Deininger, M.W., Berndt, A., Fruehauf, S., Neubauer, A., Fischer, T., Hossfeld, D.K., Schneller, F., Krause, S.W., Nerl, C., Sayer, H.G., Ottmann, O.G., Waller, C., Aulitzky, W., Le Coutre, P., Freund, M., Merx, K., Paschka, P., Konig, H., Kreil, S., Berger, U., Gschaidmeier, H., Hehlmann, R. and Hochhaus, A. (2003) Dynamics of BCR-ABL mRNA expression in first-line therapy of chronic myelogenous leukemia patients with imatinib or interferon alpha/ara-C. Leukemia, 17 (12), 2392-2400. (doi:10.1038/sj.leu.2403157).

Record type: Article

Abstract

We sought to determine dynamics of BCR-ABL mRNA expression levels in 139 patients with chronic myelogenous leukemia (CML) in early chronic phase, randomized to receive imatinib (n=69) or interferon (IFN)/Ara-C (n=70). The response was sequentially monitored by cytogenetics from bone marrow metaphases (n=803) and qualitative and quantitative RT-PCR from peripheral blood samples (n=1117). Complete cytogenetic response (CCR) was achieved in 60 (imatinib, 87%) vs 10 patients (IFN/Ara-C, 14%) after a median observation time of 24 months. Within the first year after CCR, best median ratio BCR-ABL/ABL was 0.087%, (imatinib, n=48) vs 0.27% (IFN/Ara-C, n=9, P=0.025). BCR-ABL was undetectable in 25 cases by real-time PCR, but in only four patients by nested PCR. Median best response in patients with relapse after CCR was 0.24% (n=3) as compared to 0.029% in patients with continuous remission (n=52, P=0.029). We conclude that (i) treatment with imatinib in newly diagnosed CML patients is associated with a rapid decrease of BCR-ABL transcript levels; (ii) nested PCR may reveal residual BCR-ABL transcripts in samples that are negative by real-time PCR; (iii) BCR-ABL transcript levels parallel cytogenetic response, and (iv) imatinib is superior to IFN/Ara-C in terms of the speed and degree of molecular responses, but residual disease is rarely eliminated.

This record has no associated files available for download.

More information

Published date: 2003
Keywords: epidemiology, male, fusion proteins, chronic, cytogenetics, antineoplastic agents, interferon-alpha, multicenter studies, cytarabine, germany, diagnosis, messenger, disease, middle aged, antineoplastic, recurrence, research support, patients, piperazines, treatment outcome, female, blood, prospective studies, metaphase, myeloid, genetics, proteins, prognosis, bone, bcr-abl, cross-over studies, protein, pyrimidines, non-U.S.gov't, humans, antimetabolites, leukemia, rna, bone marrow, aged, time, metabolism, observation, administration & dosage, adult, comparative study, therapy, risk factors, drug therapy

Identifiers

Local EPrints ID: 60094
URI: http://eprints.soton.ac.uk/id/eprint/60094
ISSN: 0887-6924
PURE UUID: 3d4898fe-4679-4964-ae12-960260c959ec

Catalogue record

Date deposited: 05 Sep 2008
Last modified: 15 Mar 2024 11:19

Export record

Altmetrics

Contributors

Author: M.C. Muller
Author: N. Gattermann
Author: T. Lahaye
Author: M.W. Deininger
Author: A. Berndt
Author: S. Fruehauf
Author: A. Neubauer
Author: T. Fischer
Author: D.K. Hossfeld
Author: F. Schneller
Author: S.W. Krause
Author: C. Nerl
Author: H.G. Sayer
Author: O.G. Ottmann
Author: C. Waller
Author: W. Aulitzky
Author: P. Le Coutre
Author: M. Freund
Author: K. Merx
Author: P. Paschka
Author: H. Konig
Author: S. Kreil
Author: U. Berger
Author: H. Gschaidmeier
Author: R. Hehlmann
Author: A. Hochhaus

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×